SS-31 (elamipretide) dosing — labeled use versus the research figure

SS-31 dosing has to be discussed twice, because the compound now sits in two places at once. As elamipretide it is an approved medicine — Forzinity — with a reviewed label defining route, frequency, a weight threshold, and a renal adjustment. As "SS-31" it is a research chemical with no label at all, dosed from figures borrowed out of the trial literature.

The borrowed figure happens to be accurate. What it does not carry with it is everything that made it meaningful.

Elamipretide is a mitochondria-targeting tetrapeptide administered subcutaneously, supplied as a ready-to-use sterile solution rather than a powder for reconstitution.

Two structural features of that regimen are worth noting as patterns. It is daily rather than weekly, which reflects a short duration of action. And it is weight-gated and renally adjusted — the label sets a minimum patient weight and a lower amount for severe renal impairment, which is the kind of individualised decision a supervised setting exists to make.

The number people quote for SS-31 — 40 mg subcutaneously once daily — is real, and it appears across essentially every elamipretide trial regardless of indication:

• MMPOWER-3, primary mitochondrial myopathy: 218 participants randomized to 40 mg/day subcutaneous or placebo for 24 weeks. It missed both co-primary endpoints (PMID 37268435).
• TAZPOWER open-label extension, Barth syndrome: ten patients on 40 mg subcutaneous daily, eight reaching week 168, with a cumulative 96.1 m six-minute walk improvement (P=0.003) (PMID 38602181).
• PROGRESS-HF, heart failure with reduced ejection fraction: 71 patients on placebo, 4 mg, or 40 mg daily for 28 days. Did not improve left ventricular end-systolic volume (PMID 32068002).
• ReCLAIM phase 1, dry AMD: 40 mg subcutaneous daily for 24 weeks in cohorts of 21 and 19, with safety as the primary endpoint (PMID 36246187).

The same amount, the same route, the same frequency — and mostly negative outcomes. That is the crucial context stripped away when the figure is quoted on its own. Forty milligrams daily is not a dose that reliably produces benefit; it is a dose that was tested repeatedly and worked in one population where the molecular target was precisely matched to the disease.

The approved product is a 280 mg/3.5 mL (80 mg/mL) sterile solution for subcutaneous injection, stored refrigerated at 2–8 °C, not frozen, and discarded eight days after first opening. It contains benzyl alcohol as an excipient — 20 mg per mL — which is the basis of the label's neonate contraindication.

Research-grade SS-31 is typically a lyophilized powder requiring reconstitution, where the delivered amount depends entirely on how much diluent is added and where syringe units measure volume rather than milligrams. It has no verified potency, so a milligram figure on such a vial is a claim, not a measurement — which makes matching "40 mg" from the trials an exercise in arithmetic on an unknown quantity.

An approved indication in Barth syndrome does not establish that elamipretide helps anyone else. MMPOWER-3 was rated Class I evidence that it does not improve six-minute walk distance or fatigue in primary mitochondrial myopathy at 24 weeks — a negative result in people who genuinely have mitochondrial disease, which is a strong argument against expecting benefit in healthy adults.

Labeled use also comes with things a vial cannot supply: a weight threshold, renal dose adjustment, monitoring for hypersensitivity reactions that in trials sometimes required emergency treatment, and a defined sterile formulation. Any concrete decision here belongs with qualified clinicians working from the actual prescribing information.